NMN vs NR: What the Research Actually Shows

If you have spent any time reading about longevity supplements, you have encountered the NAD+ conversation. Two compounds sit at the centre of it: nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). Both are studied as precursors that the body can convert into NAD+, a coenzyme involved in cellular energy production, DNA repair, and the activity of enzymes that research has linked to healthy ageing.

The marketing around both molecules runs hot. This guide does not. What follows is a straightforward comparison grounded in human trial data, mechanistic differences, delivery format considerations, and the regulatory landscape in New Zealand. Where the evidence is strong, we will say so. Where it is early, we will say that too.

The NAD+ story: why these molecules matter in research

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell. It plays two broad roles that the research literature consistently highlights.

First, it is essential to mitochondrial energy production. NAD+ shuttles electrons through the metabolic pathways that produce ATP, the molecule cells use as energy currency. Without adequate NAD+, these pathways slow.

Second, NAD+ is a required substrate for sirtuins (a family of enzymes involved in DNA and metabolic regulation) and PARPs (enzymes that participate in DNA repair). Every time a sirtuin or PARP does its work, it consumes one molecule of NAD+. The cell's supply is continuously being used up and must be continuously recycled.

The observation driving the entire NAD+ supplement category is this: tissue NAD+ levels decline with age. This has been measured across organisms and human tissues, and it is one of the most consistent findings in ageing research ¹. Whether replenishing NAD+ changes the trajectory of ageing in humans is a separate, harder question, and the one that honest framing requires us to keep clearly in view.

NMN and NR: where they sit in the pathway

The body recycles NAD+ primarily through what biochemists call the salvage pathway. NAD+ is consumed, broken down to nicotinamide, and then rebuilt step by step back into fresh NAD+.

Here is the simplified sequence:

Nicotinamide → NMN → NAD+

NR enters the pathway one step earlier, requiring conversion to NMN first:

NR → NMN → NAD+ (via the enzyme nicotinamide riboside kinase, NRK)

NMN is therefore one enzymatic step closer to NAD+ than NR. NMN also has a dedicated transporter, Slc12a8, that can move it directly into cells. NR does not use this pathway ². Whether this translates into a meaningful practical advantage is part of what the trials are investigating.

Both compounds are studied as ways to supply the salvage pathway with substrate, on the logic that providing more precursor may support the cell's capacity to maintain NAD+ levels. This logic is mechanistically sound. The question is what it means for outcomes.

What the human trials show

The human evidence for both NMN and NR has grown substantially, though it remains early by the standards of more established supplement categories.

NAD+ elevation: the consistent finding

Both NMN and NR reliably raise blood NAD+ markers in human trials. A 2024 review synthesising the human data reports that both NMN and NR can approximately double circulating NAD+ levels ³, with some trials suggesting NR may produce a somewhat larger increase in whole-blood NAD+. The consistent conclusion across the literature is that both compounds effectively raise the biomarker.

This finding, reliable NAD+ elevation, is the area where the evidence is most consistent. It is also the area requiring the most careful framing, because a biomarker shift is not the same as a health outcome.

Beyond biomarkers: the mixed picture

When researchers look past NAD+ levels at functional outcomes, the picture becomes more heterogeneous.

A 2024 systematic review and meta-analysis of eight NMN trials (342 participants) reported that short-term NMN supplementation at 250 to 2,000 mg per day did not show significantly positive impacts on glucose control or lipid profile in the pooled analysis ⁴. Whether particular subpopulations respond differently remains an open question that larger trials will need to answer.

A landmark 2021 trial found that 250 mg of NMN daily for 10 weeks increased muscle insulin sensitivity in prediabetic women ⁵. This was a carefully designed study, but it involved a small sample and the finding awaits replication at larger scale.

For NR, the picture is broadly similar: reliable NAD+ elevation, with inconsistent results on downstream clinical endpoints.

Both compounds raise NAD+. Whether that translates into meaningful functional outcomes for a given individual is an active research question, not a settled one.

The microbiome twist

One of the more interesting recent findings is that gut bacteria appear to play a significant role in how both NMN and NR elevate NAD+. The 2024 review highlights evidence that gut microbiota may convert both precursors to nicotinic acid, itself a potent NAD+ booster, as an intermediate step ³. Both compounds have also been observed to modulate gut bacteria in ways that increase concentrations of short-chain fatty acids (SCFAs).

This adds a layer of complexity to the comparison. If the gut microbiome is a meaningful mediator, then individual variation in gut flora could influence which precursor works better for a given person. The research is only beginning to explore this possibility.

NMN in New Zealand: regulatory considerations

For readers in New Zealand, the regulatory context around NMN is worth understanding.

NMN is currently sold in New Zealand as a dietary supplement under the Dietary Supplements Regulations 1985 (DSR 1985). These regulations, administered by Medsafe, do not require pre-market approval for dietary supplements. The sponsor (typically the importer or manufacturer) is responsible for ensuring the product meets safety, quality, and labelling requirements.

The regulatory landscape is evolving. The DSR 1985 framework has been extended multiple times, and the New Zealand government is developing new standalone legislation for natural health products. What form that legislation will take, and whether it will affect the regulatory status of specific compounds like NMN, is not yet settled.

For international context: the US FDA reversed a 2022 exclusion and confirmed NMN as a lawful dietary supplement in September 2025. Australia's TGA added NMN to its permissible ingredients list in December 2025, with a two-year market exclusivity period ⁶.

This is not a reason for alarm, and it is not a reason for complacency. Supplement regulation in New Zealand is in a transitional period, and readers interested in NMN should be aware that the framework under which it is sold may change. We will update this section as the regulatory picture develops.

Delivery format: capsules, sublingual, and liposomal

One dimension of the NMN-versus-NR comparison that often gets overlooked is how the compound reaches your bloodstream. Delivery format can affect how much of what you swallow actually becomes available to your cells.

Standard capsules deliver NMN or NR to the gastrointestinal tract, where the compound must survive stomach acid and digestive enzymes before being absorbed through the gut lining. This is the simplest and most common delivery method.

Sublingual liposomal delivery takes a different approach. A liposome is a microscopic sphere with a phospholipid shell, the same class of molecule your cell membranes are built from. Encapsulating NMN inside a liposome and delivering it sublingually (under the tongue) is designed to allow absorption across the oral mucosa, bypassing the gut and liver first-pass metabolism that degrades a portion of any orally swallowed dose before it reaches general circulation.

First-pass metabolism is a real bottleneck for many compounds. Liposomal delivery has been studied across multiple supplement categories as a way to improve the fraction that reaches the bloodstream. Whether the improvement is large enough to justify the price premium depends on the specific compound and the data behind the formulation.

For readers weighing the two approaches, we carry both. Super NMN 500 mg is a straightforward capsule: 500 mg of NMN per capsule at 99% independently assayed purity, for people who want a high-dose, no-frills option. Quicksilver NAD+ Gold is a liposomal NMN delivered as a sublingual nanoemulsion, designed to bypass first-pass metabolism. Both contain NMN. The difference is the delivery route.

For a deeper look at the full NAD+ and cellular energy landscape, including mitochondria-targeted compounds and resveratrol, our Energy and Longevity Guide covers the broader picture.

How to think about this honestly

The NAD+ precursor space is genuinely interesting science. The observation that NAD+ declines with age is robust. The ability of NMN and NR to raise NAD+ blood markers in humans is well-demonstrated. The mechanistic logic, supporting the salvage pathway that maintains this critical coenzyme, is sound.

What is not yet established is whether NAD+ elevation translates into the outcomes people are buying these supplements for: measurably slower ageing, meaningfully better energy, or clinically significant metabolic improvements. The human outcome data are promising in specific subpopulations and inconsistent in others. The trials are still too small and too short to draw definitive conclusions.

If you are interested in NMN because the mechanism is compelling and you want to be an early adopter of research you find convincing, that is a reasonable position. If you are looking for a guaranteed result, the science is not there yet for either precursor.

The most useful comparisons between NMN and NR are not about which one is "better" in an absolute sense. They are about what fits your preferences: capsule or sublingual, higher dose or targeted delivery, and how you weigh the cost difference. The NAD+ elevation data suggest both do the job. The outcome data do not yet clearly separate them.

This article describes findings from published research for general educational purposes. It is not medical advice, and nothing here is intended to diagnose, treat, cure, or prevent any disease. If you take prescription medication or have a health condition, consult a qualified healthcare professional before adding a supplement.

References

¹ Verdin, E. (2015). NAD+ in aging, metabolism, and neurodegeneration. Science, 350(6265), 1208-1213. DOI: 10.1126/science.aac4854.

² Grozio, A. et al. (2019). Slc12a8 is a nicotinamide mononucleotide transporter. Nature Metabolism, 1, 47-57. DOI: 10.1038/s42255-018-0009-4.

³ Yang, X. et al. (2024). An Updated Review on the Mechanisms, Pre-Clinical and Clinical Comparisons of Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR). Food Frontiers, 6(2), 630-643. DOI: 10.1002/fft2.511. Narrative review synthesising preclinical and clinical NAD+ precursor data, including gut-microbiome conversion of both precursors to nicotinic acid.

⁴ Chen, F. et al. (2024). Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Current Diabetes Reports. 8 RCTs, 342 participants. PMC11557618. DOI: 10.1007/s11892-024-01557-z.

⁵ Yoshino, M. et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224-1229. PMID: 33888596. DOI: 10.1126/science.abe9985.

⁶ FDA NMN status: confirmed as lawful dietary supplement, September 2025. TGA Australia: NMN added to permissible ingredients, December 2025. NZ: sold under DSR 1985; regulatory evolution ongoing.